GILD Stock Risk & Deep Value Analysis
Gilead Sciences Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About GILD Stock
We analyzed Gilead Sciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GILD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
GILD Risk Analysis & Red Flags
What Could Go Wrong
The recent $16 billion in M&A within 60 days, particularly the $7.8 billion Arcellx acquisition, introduces substantial integration and execution risks. If these acquired assets fail to meet clinical or commercial expectations, it could lead to significant financial write-downs, continued EPS dilution beyond 2026, and a material decline in investor confidence.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Significant EPS dilution projected for 2026 ($5.57-$5.67 from Arcellx acquisition) due to M&A costs.
- ⚠
Aggressive M&A strategy ($16B in 60 days) increases integration and execution risk.
- ⚠
CEO Daniel O'Day sold shares on April 28, 2026 (though under a 10b5-1 plan and retaining significant holdings).
Upcoming Risk Events
- 📅
Clinical trial failures or delays for key oncology assets
- 📅
Regulatory setbacks for new drug approvals
- 📅
Unsuccessful integration of recently acquired companies (Arcellx, Tubulis)
- 📅
Increased competition in oncology and HIV markets
When to Reconsider
- 🚪
Failure of a pivotal clinical trial for a recently acquired oncology asset (e.g., anito-cel).
- 🚪
Persistent downward revisions to future revenue or EPS guidance post-M&A integration.
- 🚪
Increased competitive pressure severely impacting Biktarvy or other core HIV revenue.
Unlock GILD Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Gilead Sciences Inc (GILD) Do?
Market Cap
$159.92B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,600
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Visit Gilead Sciences Inc WebsiteInvestment Thesis
Gilead is executing a strategic transformation to diversify its revenue base beyond HIV by aggressively acquiring innovative assets in the high-growth oncology and cell therapy sectors. While this pivot carries significant execution and integration risk, successful development and commercialization of new platforms like Arcellx's anito-cel and Tubulis' ADCs have the potential to establish new blockbuster franchises, driving sustainable long-term revenue and earnings growth for the company.
Is GILD Stock Undervalued?
Unlock the full AI analysis for GILD
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
GILD Price Targets & Strategy
12-Month Target
$158.00
Bull Case
$180.00
Bear Case
$115.00
Valuation Basis
Based on 18.3x forward P/E applied to consensus FY2026 EPS of $8.62, which implies a slight premium to current forward P/E reflecting growth from recent M&A.
Entry Strategy
Consider dollar-cost averaging on dips towards $125-$130 (near recent support levels).
Exit Strategy
Take profit at $155-$160 (analyst mean target), stop-loss at $110 if key oncology pipeline assets face significant setbacks.
Portfolio Allocation
3-5% for moderate risk tolerance, reflecting stable core business with strategic growth initiatives.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is GILD Financially Healthy?
Valuation
P/E Ratio
18.79
Forward P/E
14.85
EV/EBITDA
14.30
PEG Ratio
1.80
Price/Book
8.18
Price/Sales
6.16
Profitability
Gross Margin
78.83%
Operating Margin
34.04%
Net Margin
28.91%
Return on Equity
41.02%
Revenue Growth
2.40%
EPS
$6.78
Balance Sheet
Current Ratio
1.55
Quick Ratio
1.06
Debt/Equity
1.10
Total Debt
$28.00B
Cash & Equivalents
$5.80B
Cash Flow
Operating Cash Flow
$9.50B
Free Cash Flow
$7.50B
EBITDA
$11.50B
Other
Beta (Volatility)
0.34
Dividend Yield
2.55%
Does GILD Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable
Moat Sources
2 Identified
Gilead's moat is primarily driven by its patent-protected HIV franchise, which benefits from high switching costs for patients on established, effective regimens. Its oncology expansion aims to build new moats via novel cell therapies and ADC platforms, leveraging intellectual property and regulatory approvals for differentiated treatments.
Moat Erosion Risks
- •Patent expirations on key HIV drugs leading to generic competition
- •Intense competition and rapid innovation in the oncology market, potentially yielding superior therapies from rivals
- •Clinical or commercial failure of acquired assets, eroding investment and competitive positioning
GILD Competitive Moat Analysis
Sign up to see competitive advantages
GILD Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (typical for a large, established biopharma company, focus on pipeline updates)
Institutional Sentiment
Positive (Moderate Buy consensus with an average price target offering ~20% upside, indicating confidence in strategic direction).
Insider Activity (Form 4)
Chairman & CEO Daniel O'Day sold 10,000 shares on April 28, 2026, for approximately $1.29 million under a pre-arranged Rule 10b5-1 plan. He retains over 600,000 shares.
Options Flow
Normal options activity (no specific unusual options activity reported in the research).
Earnings Intelligence
Next Earnings
2026-05-07
Surprise Probability
Medium
Historical Earnings Pattern
Typically experiences stable stock price reaction to earnings unless forward guidance or major pipeline updates significantly diverge from expectations.
Key Metrics to Watch
Competitive Position
Top Competitor
MRK
Market Share Trend
Stable and dominant in HIV; actively gaining entry and aiming for significant share in high-growth oncology segments through strategic acquisitions.
Valuation vs Peers
Gilead typically trades in line with or at a slight discount to large-cap biopharma peers on P/E multiples, often due to past patent cliff concerns. Its recent aggressive M&A in oncology could warrant a re-rating if successful.
Competitive Advantages
- •Dominant intellectual property and market share in HIV treatments (Biktarvy)
- •Strong cash flow generation from mature assets funding oncology pivot
- •Emerging platforms in cell therapy (CAR T) and Antibody-Drug Conjugates (ADCs) through recent acquisitions
- •Global commercial infrastructure and regulatory expertise
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive GILD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (May 7, 2026)
- •Initial integration updates for Arcellx acquisition
- •Clinical trial readouts for acquired oncology assets (e.g., anito-cel, TUB-040)
Medium-Term (6-18 months)
- •Regulatory filings and potential approvals for new oncology therapies
- •Market expansion of Lenacapavir for HIV prevention (PEPFAR/Global Fund initiatives)
- •Further pipeline advancements from Tubulis' ADC platform
Long-Term (18+ months)
- •Successful establishment of leading positions in CAR T-cell therapy and ADC markets
- •Significant revenue diversification reducing reliance on HIV franchise
- •Development of next-generation blockbuster oncology drugs
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GILD?
- ✓
Positive clinical trial data for key oncology pipeline assets (e.g., Phase 3 results for anito-cel)
- ✓
Steady acceleration in oncology revenue growth (excluding acquisition effects) and successful integration updates
- ✓
Maintenance or expansion of market share in the core HIV franchise
Bull Case Analysis
See what could go right with Premium
Competing with GILD
See how Gilead Sciences Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Gilead Sciences Inc GILD | $159.9B | 2.3 | 18.8 | $30.1B | 28.9% | 2.4% | |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Merck & Co Inc MRK | $240.9B | 0.5 | 12.8 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Gilead Sciences Inc Makes Money
Gilead Sciences is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines globally. Historically, its primary revenue sources have been its market-leading treatments for HIV and hepatitis. In recent years, it has strategically expanded into oncology, particularly in advanced cell therapies and antibody-drug conjugates, through significant acquisitions to diversify its product portfolio. The company generates revenue by selling its patented drugs to healthcare providers, hospitals, and government programs worldwide, relying on its strong research and development capabilities, intellectual property protection, and global commercial infrastructure to deliver high-value therapeutics to patients.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Gilead Sciences Inc (GILD)?
As of April 30, 2026, Gilead Sciences Inc has a DVR Score of 2.3 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Gilead Sciences Inc?
Gilead Sciences Inc's market capitalization is approximately $159.9B. The company operates in the Healthcare sector within the Drug Manufacturers - General industry.
What ticker symbol does Gilead Sciences Inc use?
GILD is the ticker symbol for Gilead Sciences Inc. The company trades on the NMS.
What is the risk level for GILD stock?
Our analysis rates Gilead Sciences Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of GILD?
Gilead Sciences Inc currently has a price-to-earnings (P/E) ratio of 18.8. This is in line with broader market averages.
Does Gilead Sciences Inc pay a dividend?
Yes, Gilead Sciences Inc pays a dividend with a current yield of approximately 2.55%.
Is Gilead Sciences Inc's revenue growing?
Gilead Sciences Inc has reported revenue growth of 2.4%. The company is growing at a moderate pace.
Is GILD stock profitable?
Gilead Sciences Inc has a profit margin of 28.9%. This indicates strong profitability.
How often is the GILD DVR analysis updated?
Our AI-powered analysis of Gilead Sciences Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GILD (Gilead Sciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.